Lameck Chinula1, Agnes Moses, Satish Gopal. 1. aUNC Project-Malawi, Lilongwe, Malawi bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cUniversity of Malawi College of Medicine, Blantyre, Malawi.
Abstract
PURPOSE OF REVIEW: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA). RECENT FINDINGS: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scale-up, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. SUMMARY: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.
PURPOSE OF REVIEW: To summarize recent developments for HIV-associated malignancies (HIVAM) in low-income and middle-income countries (LMIC) with particular focus on sub-Saharan Africa (SSA). RECENT FINDINGS: Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers to non-AIDS defining cancers. Despite ART scale-up, the HIVAM burden remains high including an enormous AIDS-defining cancers burden in SSA. For Kaposi sarcoma, patients treated with ART and chemotherapy can experience good outcomes even in rural SSA, but Kaposi sarcoma heterogeneity remains insufficiently understood including virologic, immunologic, and inflammatory features that may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including vaccination and screening is underway, with benefits already apparent despite continuing high disease burden. For non-Hodgkin lymphoma, curative treatment is possible in the ART era even in SSA, and multifaceted approaches can improve outcomes further. For many other prevalent HIVAM, care and research efforts are being established to guide treatment and prevention specifically in LMIC. SUMMARY: Sustained investment for HIVAM in LMIC can help catalyze a cancer care and research agenda that benefits HIV-positive and HIV-negative patients worldwide.
Authors: Walter O Mwanda; Jackson Orem; Pingfu Fu; Cecilia Banura; Joweria Kakembo; Caren Auma Onyango; Anne Ness; Sherrie Reynolds; John L Johnson; Vivek Subbiah; Jacob Bako; Henry Wabinga; Fatuma K Abdallah; Howard J Meyerson; Christopher C Whalen; Michael M Lederman; Jodi Black; Leona W Ayers; Edward Katongole-Mbidde; Scot C Remick Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Emily A Rogena; Kenneth O Simbiri; G De Falco; L Leoncini; Leona Ayers; J Nyagol Journal: Infect Agent Cancer Date: 2015-08-24 Impact factor: 2.965
Authors: Moses Muia Masika; Javier Gordon Ogembo; Sophie Vusha Chabeda; Richard G Wamai; Nelly Mugo Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240
Authors: Aggrey Semeere; Megan Wenger; Naftali Busakhala; Nathan Buziba; Mwebesa Bwana; Winnie Muyindike; Erin Amerson; Toby Maurer; Timothy McCalmont; Philip LeBoit; Beverly Musick; Constantin Yiannoutsos; Robert Lukande; Barbara Castelnuovo; Miriam Laker-Oketta; Andrew Kambugu; David Glidden; Kara Wools-Kaloustian; Jeffrey Martin Journal: Cancer Med Date: 2016-01-28 Impact factor: 4.452
Authors: Erin G Reid; Kelly Shimabukuro; Page Moore; Richard F Ambinder; Jack D Bui; Semi Han; Otoniel Martínez-Maza; Dirk P Dittmer; David Aboulafia; Elizabeth Yu Chiao; Toby Maurer; Robert Baiocchi; Ronald Mitsuyasu; William Wachsman Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Wilfred Ngwa; Beatrice W Addai; Isaac Adewole; Victoria Ainsworth; James Alaro; Olusegun I Alatise; Zipporah Ali; Benjamin O Anderson; Rose Anorlu; Stephen Avery; Prebo Barango; Noella Bih; Christopher M Booth; Otis W Brawley; Jean-Marie Dangou; Lynette Denny; Jennifer Dent; Shekinah N C Elmore; Ahmed Elzawawy; Diane Gashumba; Jennifer Geel; Katy Graef; Sumit Gupta; Serigne-Magueye Gueye; Nazik Hammad; Laila Hessissen; Andre M Ilbawi; Joyce Kambugu; Zisis Kozlakidis; Simon Manga; Lize Maree; Sulma I Mohammed; Susan Msadabwe; Miriam Mutebi; Annet Nakaganda; Ntokozo Ndlovu; Kingsley Ndoh; Jerry Ndumbalo; Mamsau Ngoma; Twalib Ngoma; Christian Ntizimira; Timothy R Rebbeck; Lorna Renner; Anya Romanoff; Fidel Rubagumya; Shahin Sayed; Shivani Sud; Hannah Simonds; Richard Sullivan; William Swanson; Verna Vanderpuye; Boateng Wiafe; David Kerr Journal: Lancet Oncol Date: 2022-05-09 Impact factor: 54.433
Authors: Susan Pereira Ribeiro; Jeffrey M Milush; Edecio Cunha-Neto; Esper G Kallas; Jorge Kalil; Luiz Felipe D Passero; Peter W Hunt; Steven G Deeks; Douglas F Nixon; Devi SenGupta Journal: PLoS One Date: 2016-11-18 Impact factor: 3.240